LGND Overview

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.

Wall Street analysts forecast LGND stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LGND is237.20 USD with a low forecast of 220.00 USD and a high forecast of 270.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Ligand Pharmaceuticals Inc revenue for the last quarter amounts to 59.67M USD, increased 39.37

Ligand Pharmaceuticals Inc. EPS for the last quarter amounts to 2.17 USD, decreased -232.32

Ligand Pharmaceuticals Inc (LGND) has 47 emplpoyees as of April 15 2026.

Today LGND has the market capitalization of 4.63B USD.